These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The relative roles of MHC and non-MHC genes in heart and skin allograft survival. Katz SM, Liebert M, Gill TJ, Kunz HW, Cramer DV, Guttmann RD. Transplantation; 1983 Jul; 36(1):96-101. PubMed ID: 6346618 [Abstract] [Full Text] [Related]
4. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Chowdhury NC, Saborio DV, Garrovillo M, Chandraker A, Magee CC, Waaga AM, Sayegh MH, Jin MX, Oluwole SF. Transplantation; 1998 Oct 27; 66(8):1059-66. PubMed ID: 9808492 [Abstract] [Full Text] [Related]
7. Suppression of kidney allograft rejection across full MHC barriers by recipient-specific antibodies to class II MHC antigens. Priestley CA, Spencer SC, Sawyer GJ, Fabre JW. Transplantation; 1992 May 27; 53(5):1024-32. PubMed ID: 1585464 [Abstract] [Full Text] [Related]
8. Cyclosporine and skin allografts for the treatment of thermal injury. I. Extensive graft survival with low-level long-term administration and prolongation in a rat burn model. Hewitt CW, Black KS, Aguinaldo AM, Achauer BM, Howard EB. Transplantation; 1988 Jan 27; 45(1):8-12. PubMed ID: 3276067 [Abstract] [Full Text] [Related]
9. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin. Dono K, Maki T, Wood ML, Monaco AP. Transplantation; 1995 Dec 15; 60(11):1268-73. PubMed ID: 8525521 [Abstract] [Full Text] [Related]
11. Cyclosporine and experimental skin allografts. II. Indefinite survival and development of specific immunologic unresponsiveness. Towpik E, Kupiec-Weglinski JW, Schneider TM, Tyler D, Padberg W, Araneda D, Tilney NL. Transplantation; 1985 Dec 15; 40(6):714-8. PubMed ID: 3907046 [Abstract] [Full Text] [Related]
12. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, Kohsaka M, Ochiai T. Transplantation; 1988 Jan 15; 45(1):206-9. PubMed ID: 2447690 [Abstract] [Full Text] [Related]
14. Short-course cyclosporin A therapy for definite allograft valve survival immunosuppression in allograft valve operations. Yankah AC, Wottge HU, Müller-Ruchholtz W. Ann Thorac Surg; 1995 Aug 15; 60(2 Suppl):S146-50. PubMed ID: 7646147 [Abstract] [Full Text] [Related]
15. Indirect T cell allorecognition: a cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens. Sawyer GJ, Dalchau R, Fabre JW. Transpl Immunol; 1993 Aug 15; 1(1):77-81. PubMed ID: 8081765 [Abstract] [Full Text] [Related]
20. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Transplantation; 1997 Feb 15; 63(3):359-64. PubMed ID: 9039923 [Abstract] [Full Text] [Related] Page: [Next] [New Search]